Understanding how metformin works in young people with type 2 diabetes
A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes
This study is looking into why metformin, a common diabetes medication, sometimes doesn't work well for young people, and it aims to find out what factors affect its effectiveness so that doctors can better tailor treatments for each individual.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10821298 on NIH RePORTER |
What this research studies
This research investigates why metformin, a common medication for type 2 diabetes, often fails to control blood sugar levels in young patients. The study aims to identify the factors that influence how well metformin works in youth by analyzing genetic, clinical, and physiological data. Researchers will develop a model to predict how different individuals respond to metformin and create a personalized dosing tool to improve treatment outcomes. Ultimately, this research seeks to enhance the effectiveness of metformin therapy for young people with type 2 diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are youth aged 12 to 20 years who have been diagnosed with type 2 diabetes and are currently being treated with metformin.
Not a fit: Patients who do not have type 2 diabetes or are not within the age range of 12 to 20 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for young patients with type 2 diabetes.
How similar studies have performed: Previous research has shown promise in understanding pharmacokinetics and pharmacodynamics in other populations, but this specific approach in youth with type 2 diabetes is relatively novel.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Srinivasan, Shylaja — University of California, San Francisco
- Study coordinator: Srinivasan, Shylaja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.